The efficacy and safety of anamorelin among patients with diabetes.

Kenju AndoTateaki NaitoSatoshi HamauchiKeita MiuraYuichiro NishiboriAyumi TonshoSuguru MatsudaMeiko MoritaMotoki SekikawaKosei DoshitaHiroaki KodamaMichitoshi YabeNoboru MorikawaYuko IidaNobuaki MamesayaHaruki KobayashiKo RyoKazushige WakudaAkira OnoHirotsugu KenmotsuHaruyasu MurakamiKentaro YamazakiToshiaki Takahashi

Published in: International journal of clinical oncology (2024)

Patients with diabetes and cancer cachexia are less likely to gain weight with anamorelin despite a high risk of hyperglycaemic adverse events.

Keyphrases

papillary thyroid
body mass index
squamous cell
weight loss
weight gain
squamous cell carcinoma
body weight
young adults